Lotus Pharmaceutical Co (TPE:1795) EV-to-EBITDA : 11.01 (As of Mar. 05, 2025)

Lotus Pharmaceutical Co EV-to-EBITDA Chart

Lotus Pharmaceutical Co Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBITDA		Get a 7-Day Free Trial					16.17	10.64	10.37	13.57	11.90

Lotus Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-EBITDA	Get a 7-Day Free Trial															11.05	11.90	13.27	13.08	10.84

Competitive Comparison of Lotus Pharmaceutical Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lotus Pharmaceutical Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lotus Pharmaceutical Co's EV-to-EBITDA falls into.

Lotus Pharmaceutical Co EV-to-EBITDA Calculation

Lotus Pharmaceutical Co's EV-to-EBITDA for today is calculated as:

Lotus Pharmaceutical Co's current Enterprise Value is NT$79,733 Mil.
Lotus Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$7,240 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Pharmaceutical Co  (TPE:1795) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Lotus Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:

Lotus Pharmaceutical Co's share price for today is NT$267.50.
Lotus Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$16.460.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Lotus Pharmaceutical Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lotus Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Lotus Pharmaceutical Co Business Description